May 14, 1992 |
Biotechnology Patent Dispute Settled: Amgen Inc. in Thousand Oaks said it resolved a patent dispute with Chugai Pharmaceutical Co. over rights to a new infection-fighting drug for cancer patients. Under the agreement, Chugai dropped its two existing U.S. patents on the biotechnology-derived drug and, in the event it secures any U.S. patents in the future, granted Amgen royalty-free licenses to sell the drug in North America.
March 30, 1993 |
The stock market had a conniption last month when biotechnology giant Amgen Inc. said its sizzling sales growth was slowing a bit. Amgen, a Wall Street darling when its sales soared each quarter, saw its stock plunge 25% that day. Peeved shareholders then filed the obligatory lawsuits, alleging Amgen misled investors about its prospects. Amgen denies that, but small wonder the holders are upset.
March 8, 1996 |
Amgen's Neupogen OKd for HIV Treatment in Britain: Although Neupogen won approval there for treating people with advanced HIV infection, it must finish undergoing clinical trials before the U.S. Food and Drug Administration will consider approving it for AIDS treatment in the United States. Thousand Oaks-based Amgen Inc.'
May 13, 1992 |
UC Irvine on Tuesday awarded Amgen Inc. a 1991 Medical Product of the Year Award for its development of a drug that stimulates blood cell growth in bone marrow, a technique that helps patients overcome the toxic effects of chemotherapy. "It's the No. 1 blockbuster drug to come out of the biomedical industry in at least five years," said Dr. Andrew Senyei, a judge in the annual competition, sponsored by UCI's Medical Research and Education Society. "It is a billion-dollar drug."
December 10, 1996
The U.S. Patent and Trademark Office has issued another patent to Amgen Inc. covering various product rights to its biotechnology drug G-CSF, which is sold under the trade name Neupogen. Neupogen, which generated sales last year of $936 million, was first approved for sale by the Food and Drug Administration in 1991. Amgen, based in Thousand Oaks, already has patents on the drug that cover various aspects of its manufacture.
April 5, 1993 |
The stock market had a conniption in February when biotechnology giant Amgen Inc. said its sizzling sales growth was slowing a bit. Amgen, a Wall Street darling when its sales were soaring every quarter, saw its stock plunge 25% that day. Overall, Amgen's total market value has fallen $5 billion in four months, to about $4.7 billion. Shares were traded at $78 each in early December, but closed Friday at $36, off $1. But the Street is focusing on the wrong problem.